Endo International | ENDP - Les Charges D'Exploitation



Les Charges D'Exploitation Changement Date
AbbVie USD 10.81B 13.45B 2025-12
Amarin USD 51.37M 14.6M 2025-09
ANI Pharmaceuticals USD 217.93M 287.88M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Coherus Biosciences USD 53.03M 43.41M 2025-03
Eli Lilly USD 10.31B 1.09B 2025-12
Heron Therapeutics USD 38.47M 4M 2024-09
Hikma Pharmaceutical USD 1.34B 702M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
Merck USD 10.16B 558M 2025-12
Novartis USD 9.86B 115M 2025-09
Pacira USD 193.68M 27.32M 2025-12
Perrigo USD 1.03B 75.3M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Phibro Animal Health USD 332.36M 20.68M 2025-12
Supernus Pharmaceuticals USD 197.75M 54.54M 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Teva Pharmaceutical Industries USD 4.22B 812M 2025-12
Xeris Pharmaceuticals USD 67.65M 590K 2025-09
Zoetis USD 1.55B 3.85B 2025-12